Table 1.
Gene ID | Gene Symbol | Gene Description | ChipInspector | + GenePattern |
---|---|---|---|---|
208 | AKT2 | v-akt murine thymoma viral oncogene homolog 2 | −1.12 | |
841 | CASP8 | caspase 8, apoptosis-related cysteine peptidase | −1.08 | |
942 | CD86 | CD86 molecule | 1.21 | |
6373 | CXCL11 | chemokine (C-X-C motif) ligand 11 | −1.17 | |
4283 | CXCL9 | chemokine (C-X-C motif) ligand 9 | −1.33 | |
2353 | FOS | FBJ murine osteosarcoma viral oncogene homolog | 1.46 | |
3454 | IFNAR1 | interferon (alpha, beta and omega) receptor 1 | 1.15 | |
3455 | IFNAR2 | interferon (alpha, beta and omega) receptor 2 | −1.1 | |
3663 | IRF5 | interferon regulatory factor 5 | −1.14 | |
3725 | JUN | jun proto-oncogene | 1.16 | 1.14 |
3929 | LBP | lipopolysaccharide binding protein | −1.31 | −1.59 |
5604 | MAP2K1 | mitogen-activated protein kinase kinase 1 | −1.14 | |
5609 | MAP2K7 | mitogen-activated protein kinase kinase 7 | 1.12 | |
6885 | MAP3K7 | mitogen-activated protein kinase kinase kinase 7 | −1.09 | |
1326 | MAP3K8 | mitogen-activated protein kinase kinase kinase 8 | −1.16 | |
5594 | MAPK1 | mitogen-activated protein kinase 1 | 1.15 | |
5602 | MAPK10 | mitogen-activated protein kinase 10 | −1.13 | |
1432 | MAPK14 | mitogen-activated protein kinase 14 | −1.12 | |
5599 | MAPK8 | mitogen-activated protein kinase 8 | −1.08 | |
5291 | PIK3CB | phosphoinositide-3-kinase, catalytic, beta polypeptide | −1.14 | −1.4 |
5294 | PIK3CG | phosphoinositide-3-kinase, catalytic, gamma polypeptide | −1.1 | |
5295 | PIK3R1 | phosphoinositide-3-kinase, regulatory subunit 1 (alpha) | 1.18 | |
5296 | PIK3R2 | phosphoinositide-3-kinase, regulatory subunit 2 (beta) | 1.09 | |
8503 | PIK3R3 | phosphoinositide-3-kinase, regulatory subunit 3 (gamma) | −1.12 | |
6772 | STAT1 | signal transducer and activator of transcription 1, 91kDa | −1.14 | |
23118 | TAB2 | TGF-beta activated kinase 1/MAP3K7 binding protein 2 | 1.11 | |
148022 | TICAM1 | toll-like receptor adaptor molecule 1 | 1.16 | 1.16 |
Previously published data (Hur et al., 2011) represented as relative fold changes in sural nerve gene expression between neuropathy patients who either worsened in their neuropathy (progressors) or had no change in neuropathy (non-progressors), with non-progressors used as the reference set for the two different analyses (ChipInspector and ChipInspector + GenePattern).